Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer (Q71687184)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

title

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

Figg WD

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Sartor O

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Cooper MR

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Thibault A

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Bergan RC

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Dawson N

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Reed E

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

Myers CE

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

publication date

1 April 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

20 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

412-414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

STUDIES ON PROSTATIC CANCER

20 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980323-4

10.1016/S0002-9343(99)80323-4

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7535978%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference